AlZaim Ibrahim, Hammoud Safaa H, Al-Koussa Houssam, Ghazi Alaa, Eid Ali H, El-Yazbi Ahmed F
Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon.
Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Front Cardiovasc Med. 2020 Nov 17;7:602088. doi: 10.3389/fcvm.2020.602088. eCollection 2020.
Adipose tissue is a critical regulator of systemic metabolism and bodily homeostasis as it secretes a myriad of adipokines, including inflammatory and anti-inflammatory cytokines. As the main storage pool of lipids, subcutaneous and visceral adipose tissues undergo marked hypertrophy and hyperplasia in response to nutritional excess leading to hypoxia, adipokine dysregulation, and subsequent low-grade inflammation that is characterized by increased infiltration and activation of innate and adaptive immune cells. The specific localization, physiology, susceptibility to inflammation and the heterogeneity of the inflammatory cell population of each adipose depot are unique and thus dictate the possible complications of adipose tissue chronic inflammation. Several lines of evidence link visceral and particularly perivascular, pericardial, and perirenal adipose tissue inflammation to the development of metabolic syndrome, insulin resistance, type 2 diabetes and cardiovascular diseases. In addition to the implication of the immune system in the regulation of adipose tissue function, adipose tissue immune components are pivotal in detrimental or otherwise favorable adipose tissue remodeling and thermogenesis. Adipose tissue resident and infiltrating immune cells undergo metabolic and morphological adaptation based on the systemic energy status and thus a better comprehension of the metabolic regulation of immune cells in adipose tissues is pivotal to address complications of chronic adipose tissue inflammation. In this review, we discuss the role of adipose innate and adaptive immune cells across various physiological and pathophysiological states that pertain to the development or progression of cardiovascular diseases associated with metabolic disorders. Understanding such mechanisms allows for the exploitation of the adipose tissue-immune system crosstalk, exploring how the adipose immune system might be targeted as a strategy to treat cardiovascular derangements associated with metabolic dysfunctions.
Front Cardiovasc Med. 2020-11-17
Front Endocrinol (Lausanne). 2016-4-13
Front Endocrinol (Lausanne). 2013-6-12
Discov Med. 2009-8
Front Physiol. 2020-1-29
Biochem Pharmacol. 2024-4
Front Endocrinol (Lausanne). 2021
Horm Mol Biol Clin Investig. 2017-6-23
Trends Immunol. 2019-8-6
J Am Heart Assoc. 2024-6-18
Nat Rev Endocrinol. 2023-12
Front Cardiovasc Med. 2023-8-14
Immunol Cell Biol. 2020-11
Cardiovasc Pathol. 2020-7-3
Diabetes Metab Res Rev. 2021-3
Naunyn Schmiedebergs Arch Pharmacol. 2020-12
Cell Rep. 2020-7-7
Cell Mol Gastroenterol Hepatol. 2020
Am J Med Sci. 2020-5-28